Cannabigerol

Rare Cannabinoid Company Launches THC + CBG Relief Gummies - The Ultimate Edible for Physical Wellness

Retrieved on: 
Wednesday, November 29, 2023
Sleep, Brain, Cannabinoid, Edible, THC, CBGA, Euphoria, Gummy candy, CBN, Cannabis, Multimedia, Nervous system, Rest, CBDV, CBC, Health, Relaxation, Well-order, CBG, Online shopping, CBD, Cannabigerol

HONOLULU, Nov. 29, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company, a leading innovator in the world of hemp-based products, is thrilled to announce the launch of its latest creation: THC + CBG Relief Gummies. This groundbreaking edible offers an enticing combination of Delta-9-THC, CBG, and CBD, providing consumers with an all-natural way to support their physical wellness.

Key Points: 
  • HONOLULU, Nov. 29, 2023 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company, a leading innovator in the world of hemp-based products, is thrilled to announce the launch of its latest creation: THC + CBG Relief Gummies .
  • These gummies bring together the best of THC, CBG, and CBD, offering an enjoyable and effective way to support physical wellness."
  • THC + CBG Relief Gummies are the perfect fusion of THC Gummies and CBG Gummies , also with the benefits of CBD.
  • To learn more about THC + CBG Relief Gummies and Rare Cannabinoid Company's other innovative hemp-based products, visit their website.

Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay

Retrieved on: 
Monday, July 17, 2023
Aureus, CBD, TSX, FSE, Cannabigerol, CBG, Rare-earth element, Fine chemical, Cannabidiol

TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority owned subsididery Santa Marta Golden Hemp the Company has completed the commercial export of aureus branded products into Paraguay.

Key Points: 
  • TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority owned subsididery Santa Marta Golden Hemp the Company has completed the commercial export of aureus branded products into Paraguay.
  • The commercial export included Aureus branded purified Cannabidiol (CBD) and Cannabigerol (CBG) which is a part of the company’s portfolio of cannabinoid active pharmaceutical ingredients).
  • This transaction also marks the 17th international market for Aureus branded products and 20th market for all Avicanna products which further demonstrates the company’s capabilities in navigating complex regulatory processes for its commercialization efforts internationally.

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS

Retrieved on: 
Friday, May 12, 2023
Food, Bank statement, Sandhill, Active ingredient, CBG, The Company, SEDAR, Drug discovery, Protein engineering, TSX, Growth, WLLW, Biocatalysis, M3, Willow Springs Distilling Company, Willow, Fine chemical, Renewable energy, Cannabigerol

Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended March 31, 2023 are available on SEDAR at www.sedar.com .

Key Points: 
  • Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended March 31, 2023 are available on SEDAR at www.sedar.com .
  • On February 22, 2023, Willow announced the appointment of Jim Lalonde, Ph.D. as its newest independent member of the Company's Board of Directors, effective February 21, 2023.
  • Willow ended the quarter with strong liquidity, including approximately $10.5 million of cash as of March 31, 2023, with the Company's approved annual budget expected to be fully funded for 2023.
  • The Company reported revenue of $274,000 for the quarter compared to nil revenue for the first quarter of 2022.

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

Retrieved on: 
Friday, April 14, 2023
Chewels, US Foods, Neuropharmacology, Dermatitis, Atopic dermatitis, Doctor of Philosophy, Nicotine gum, Incidence, Acquisition, Patient, DMPK, API, Opioid overdose, Disease, Maintenance, Substance dependence, Nicotine, Research, USD, CBG, CDC, CGMP, Addiction, Smoking, Cannabidiol, Skin, Safety, British Columbia Centre for Disease Control, Opioid use disorder, Psoriasis, Translational medicine, European, Immune system, Vitiligo, LC-MS/MS, Opioid, Fatal, ASX, QPS, Food, Pharmaceutical industry, MD, Toxicology, CBD, Cannabigerol, Eurofins Scientific

Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.

Key Points: 
  • Over the years, QPS has adopted additional services, including Neuropharmacology, DMPK, Toxicology, Translational Medicine, Early Phase Clinical Research and Phase II – IV Clinical Research.
  • QPS is currently drafting pre-investigational new drug (pre-IND) submissions for both the European Union’s European Medicines Agency (‘EMA’) and the US Food and Drug Administration (‘FDA’) for the CannQuit™ and ReneCann™ Products.
  • CEO and Managing Director, Mr Joel Latham said; “QPS is a perfect fit for us to develop these products across the globe.
  • Data collected by Eurofins on the quality and stability of the products will be key components of future regulatory packages.

WILLOW & SUANFARMA ANNOUNCE COMPLETED DEVELOPMENT AND MANUFACTURING PROCESS FOR CBG AND COMMITMENT TO THE PRODUCTION OF NEW MOLECULES IN A NATURAL WAY

Retrieved on: 
Wednesday, March 22, 2023
Active ingredient, Pharma, Health, AB, Fermentation, CBG, WILLOW, CDMO, TSX, API, WLLW, Industrial, M3, Technology transfer, Food, Wellness, Fine chemical, Cannabigerol

The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.

Key Points: 
  • The 36 m3 scaling-up production batches required for the forthcoming qualification and registration will be completed during 2023.
  • SUANFARMA' s CIPAN manufacturing site has significant expertise as a CDMO in fermentation and purification technologies under the highest standards of quality.
  • WILLOW BIOSCIENCES is a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients using its FutureGrown™ platform.
  • "CIPAN has proven itself a highly capable manufacturing partner with the efficient scaling and production of our first ingredient, CBG.

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product

Retrieved on: 
Wednesday, December 14, 2022
RHO, Fibromyalgia, Associate, Absorption, Science, Cannabis, Formulary, Toronto Stock Exchange, FSE, Dermatology, Terpene, Research, Rheumatoid arthritis, Nursing, Clinical trial, Inflammation, Chronic pain, McGill University, Wellness, Risk, CRS, TSX, R, Quality of life, CBG, News, Overalls, CBD, Social media, Patient, Data collection, Physician, Offering, Menthol, Cannabinoid, Eugenol, Muscle, Medical Affairs Bureau, SEDAR, Osteoarthritis, Arthritis, Medical device, Drug, Medicine, Pharmaceutical industry, Cannabigerol, Cannabidiol

The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.

Key Points: 
  • The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment.
  • The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider.
  • Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO.
  • The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus.

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Retrieved on: 
Tuesday, November 29, 2022
US Foods, Laboratory, Australian Securities Exchange, Chemistry, Vitiligo, Inflammatory bowel disease, Anxiety, Patient, Doctor of Philosophy, Incidence, Environment, Addiction, Immune system, Skin, Pain, Pigment, ASX, OSA, Rheumatoid arthritis, FDA, Concussion, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Cannabinoid, Disease, Patent, American depositary receipt, CDMO, Atopic dermatitis, Safety, Dermatitis, Acquisition, Contract research organization, Pharmacology, COPD, CBG, Asthma, U.S. FDA, Psoriasis, Bronchitis, Pharmaceutical industry, Vaccine, Cannabigerol, Cannabidiol, Eurofins Scientific, MD

A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.

Key Points: 
  • A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.
  • In the study, ReneCann reduced disease scores in patients with each of the target skin diseases.
  • ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.

Cannadips Europe introduces 8 new variations to its product line, including CBG Caffeine pouches

Retrieved on: 
Friday, November 11, 2022
Cream, Ice Cream Cake (EP), American Spice Trade Association, Horchata, Solution, CBG, Nicotine, Cannabigerol, Water, Tea, Coffee, CBD, Caffeine

To continue the mission of promoting a nicotine-free pouch alternative, the brand has recently expanded its portfolio with new innovative flavours and different collections such as CBG Caffeine pouches.

Key Points: 
  • To continue the mission of promoting a nicotine-free pouch alternative, the brand has recently expanded its portfolio with new innovative flavours and different collections such as CBG Caffeine pouches.
  • Cannabigerol (CBG) is a type of cannabinoid from the cannabis plant that may be associated with certain claimed benefits.
  • By pairing CBG with caffeine, Cannadips hope to provide yet another nicotine-free pouch substitute that can be used for various applications.
  • Brands under the company include Cannadips a pouch-in-mouth CBD product, Elevar Hemp premium CBD oral strips, and Voon mini white CBD hemp pouches.

Cannadips Europe introduces 8 new variations to its product line, including CBG Caffeine pouches

Retrieved on: 
Friday, November 11, 2022
Cream, Ice Cream Cake (EP), American Spice Trade Association, Horchata, Solution, CBG, Nicotine, Cannabigerol, Water, Tea, Coffee, CBD, Caffeine

To continue the mission of promoting a nicotine-free pouch alternative, the brand has recently expanded its portfolio with new innovative flavours and different collections such as CBG Caffeine pouches.

Key Points: 
  • To continue the mission of promoting a nicotine-free pouch alternative, the brand has recently expanded its portfolio with new innovative flavours and different collections such as CBG Caffeine pouches.
  • Cannabigerol (CBG) is a type of cannabinoid from the cannabis plant that may be associated with certain claimed benefits.
  • By pairing CBG with caffeine, Cannadips hope to provide yet another nicotine-free pouch substitute that can be used for various applications.
  • Brands under the company include Cannadips a pouch-in-mouth CBD product, Elevar Hemp premium CBD oral strips, and Voon mini white CBD hemp pouches.

CBDistillery Announces Groundbreaking Research Finding CBG + CBD Can Significantly Reduce Temporary Anxiety

Retrieved on: 
Wednesday, July 13, 2022
Anxiety, Cannabinoid, Marketing, Pathfinder, CBN, Sleep, Education, Contract research organization, Cannabis, Appetite, CRO, CEO, COO, Population, CBD, Investment, CBG, Mars, Research, Quality of life, Participation, Relaxation, Industry, Cannabinol, NASDAQ, Coffee, Dietary supplement, Management, Cannabigerol

83% of participants reported that CBDistillery's Daytime Synergy 500mg CBG + 500mg CBD tincture had some level of improvement on their quality of life.

Key Points: 
  • 83% of participants reported that CBDistillery's Daytime Synergy 500mg CBG + 500mg CBD tincture had some level of improvement on their quality of life.
  • 9-out-of-10 participants reported that they will recommend CBDistillery's Daytime Synergy 500mg CBG + 500mg CBD tincture to others dealing with mild or temporary anxiety.
  • Participants reported that CBDistillery's Daytime Synergy 500mg CBG + 500mg CBD tincture was significantly more efficacious at managing mild or temporary anxiety than other activities.
  • Majority of participants reported that mild or temporary anxiety had less of an impact on their overall quality of life while using CBDistillery's Daytime Synergy 500mg CBG + 500mg CBD tincture.